SG10201705190TA - Nasal influenza vaccine composition - Google Patents

Nasal influenza vaccine composition

Info

Publication number
SG10201705190TA
SG10201705190TA SG10201705190TA SG10201705190TA SG10201705190TA SG 10201705190T A SG10201705190T A SG 10201705190TA SG 10201705190T A SG10201705190T A SG 10201705190TA SG 10201705190T A SG10201705190T A SG 10201705190TA SG 10201705190T A SG10201705190T A SG 10201705190TA
Authority
SG
Singapore
Prior art keywords
vaccine composition
influenza vaccine
nasal influenza
nasal
composition
Prior art date
Application number
SG10201705190TA
Inventor
Hideki Hasegawa
Tadaki Suzuki
Akira Ainai
Taizou Kamishita
Takashi Miyazaki
Original Assignee
Japan As Represented By Director General Of Nat Inst Of Infectious Diseases
Toko Yakuhin Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan As Represented By Director General Of Nat Inst Of Infectious Diseases, Toko Yakuhin Kogyo Kk filed Critical Japan As Represented By Director General Of Nat Inst Of Infectious Diseases
Publication of SG10201705190TA publication Critical patent/SG10201705190TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
SG10201705190TA 2012-12-28 2013-10-23 Nasal influenza vaccine composition SG10201705190TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012287900 2012-12-28

Publications (1)

Publication Number Publication Date
SG10201705190TA true SG10201705190TA (en) 2017-07-28

Family

ID=51020588

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201705190TA SG10201705190TA (en) 2012-12-28 2013-10-23 Nasal influenza vaccine composition
SG11201504648TA SG11201504648TA (en) 2012-12-28 2013-10-23 Nasal influenza vaccine composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201504648TA SG11201504648TA (en) 2012-12-28 2013-10-23 Nasal influenza vaccine composition

Country Status (27)

Country Link
US (2) US20160015800A1 (en)
EP (2) EP3566715A1 (en)
JP (1) JP6247639B2 (en)
KR (1) KR102071099B1 (en)
CN (2) CN110038123A (en)
AU (1) AU2013367751B2 (en)
BR (1) BR112015015523B1 (en)
CA (1) CA2894223C (en)
CY (1) CY1122372T1 (en)
DK (1) DK2939692T3 (en)
ES (1) ES2731899T3 (en)
HK (1) HK1209646A1 (en)
HU (1) HUE044434T2 (en)
IL (1) IL239284B (en)
LT (1) LT2939692T (en)
MX (1) MX371154B (en)
MY (1) MY173503A (en)
NZ (1) NZ708922A (en)
PH (1) PH12015501482A1 (en)
PL (1) PL2939692T3 (en)
PT (1) PT2939692T (en)
RU (1) RU2652296C2 (en)
SG (2) SG10201705190TA (en)
SI (1) SI2939692T1 (en)
TR (1) TR201910293T4 (en)
TW (1) TWI624280B (en)
WO (1) WO2014103488A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9603919B2 (en) * 2009-03-31 2017-03-28 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
US9408880B2 (en) 2013-12-20 2016-08-09 Katherine Rose Kovarik Method and system for prevention and treatment of allergic and inflammatory diseases
US9585920B2 (en) 2011-02-04 2017-03-07 Katherine Rose Kovarik Method and system for treating cancer cachexia
US9457077B2 (en) 2009-11-18 2016-10-04 Katherine Rose Kovarik Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
FI3162378T3 (en) 2014-06-25 2024-03-18 Toko Yakuhin Kogyo Kk Influenza vaccine nasal vaccination system
JP6322844B2 (en) 2014-06-25 2018-05-16 東興薬品工業株式会社 Nasal spray nozzle used for medical syringes
CN105342982B (en) * 2015-11-19 2018-08-28 上海现代药物制剂工程研究中心有限公司 Influenza vaccines immune formulation of nose administration and preparation method thereof
TW201722472A (en) * 2015-11-27 2017-07-01 Nitto Denko Corp Vaccine pharmaceutical composition for oral administration and method for manufacturing vaccine pharmaceutical composition for oral administration
KR101944953B1 (en) * 2016-07-29 2019-02-01 메타볼랩(주) Antiviral composition against influenza virus for mucous membranes
CA3075423A1 (en) * 2017-10-05 2019-04-11 Toko Yakuhin Kogyo Co., Ltd. Nasal hepatitis b vaccine composition and method for producing same
WO2021002355A1 (en) 2019-07-03 2021-01-07 アイリス株式会社 Pharmaceutical composition for treating influenza virus infections
CN113117093B (en) * 2019-12-31 2024-02-09 辽宁成大生物股份有限公司 Promoter suitable for nasal mucosa delivery of influenza vaccine
WO2023120535A1 (en) * 2021-12-20 2023-06-29 東興薬品工業株式会社 Vaccine adjuvant agent containing polyacrylic acid polymer and use of same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215739A (en) * 1989-04-05 1993-06-01 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
US5158761A (en) * 1989-04-05 1992-10-27 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
JPH0678245B2 (en) * 1989-07-04 1994-10-05 東興薬品工業株式会社 Influenza vaccine gel formulation for nasal spray administration
US20090081253A1 (en) * 2005-03-23 2009-03-26 Glaxosmithkline Biologicals S.A. Composition
PL2011467T3 (en) 2006-04-21 2021-04-06 Toko Yakuhin Kogyo Kabushiki Kaisha Fluid container and airless fluid dispensing system
MY149623A (en) 2006-04-21 2013-09-13 Toko Yakuhin Kogyo Kk Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation
US9603919B2 (en) * 2009-03-31 2017-03-28 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration

Also Published As

Publication number Publication date
NZ708922A (en) 2019-10-25
RU2015130634A (en) 2017-02-01
IL239284B (en) 2020-02-27
AU2013367751A1 (en) 2015-07-09
HUE044434T2 (en) 2019-10-28
LT2939692T (en) 2019-08-12
EP2939692A1 (en) 2015-11-04
PH12015501482B1 (en) 2015-09-21
AU2013367751A8 (en) 2015-08-27
EP2939692A4 (en) 2016-07-06
AU2013367751B2 (en) 2018-02-08
TWI624280B (en) 2018-05-21
EP3566715A1 (en) 2019-11-13
TR201910293T4 (en) 2019-07-22
CA2894223C (en) 2021-04-06
KR20150102995A (en) 2015-09-09
SG11201504648TA (en) 2015-07-30
SI2939692T1 (en) 2019-10-30
WO2014103488A1 (en) 2014-07-03
CN104884086A (en) 2015-09-02
DK2939692T3 (en) 2019-07-08
MX2015008380A (en) 2016-03-15
MY173503A (en) 2020-01-29
MX371154B (en) 2020-01-20
BR112015015523B1 (en) 2023-02-23
CA2894223A1 (en) 2014-07-03
US20160015800A1 (en) 2016-01-21
KR102071099B1 (en) 2020-01-29
CN110038123A (en) 2019-07-23
EP2939692B1 (en) 2019-04-24
PH12015501482A1 (en) 2015-09-21
JP6247639B2 (en) 2017-12-13
HK1209646A1 (en) 2016-04-08
CY1122372T1 (en) 2021-01-27
JPWO2014103488A1 (en) 2017-01-12
BR112015015523A2 (en) 2017-07-11
RU2652296C2 (en) 2018-04-25
ES2731899T3 (en) 2019-11-19
IL239284A0 (en) 2015-07-30
PT2939692T (en) 2019-06-27
PL2939692T3 (en) 2019-10-31
US20190091324A1 (en) 2019-03-28
TW201427724A (en) 2014-07-16

Similar Documents

Publication Publication Date Title
HK1209646A1 (en) Nasal influenza vaccine composition
HK1207967A1 (en) Vaccine
EP2758038A4 (en) Novel influenza hemagglutinin protein-based vaccines
HK1212906A1 (en) Vaccine compositions
PL2647387T3 (en) Vaccine Composition
PT2806891T (en) Parainfluenza virus 5 based vaccines
EP2876161A4 (en) Vaccine
GB201223386D0 (en) Vaccine
HK1200845A1 (en) Influenza hemagglutinin variants
EP2852396A4 (en) Influenza vaccine constructs
ZA201300395B (en) Influenza vaccine
ZA201500656B (en) Marker vaccine
HK1201283A1 (en) Influenza c virus and vaccine
ZA201405107B (en) Mtb-c vaccine against asthma
EP2822599A4 (en) Vaccine formulation
HK1209140A1 (en) Bovine influenza c virus compositions
HK1200342A1 (en) Nasal formulation
HK1209647A1 (en) Dengue virus vaccine composition
DK2846829T3 (en) Vaccine combinations
GB201217321D0 (en) Vaccine
GB201210226D0 (en) Vaccine
GB201206169D0 (en) Vaccine
GB201205599D0 (en) Vaccine
GB201202090D0 (en) Vaccine